Organization & Developments: Flexion Therapeutics

Parents

2016: Biotech Forum Daily Digest: Tesaro's Huge Week! Brexit Losses Gone, Spotlight On Applied Genetics Technologies
2017: Flexion Therapeutics: Updates To Thesis - Flexion Therapeutics, Inc. (NASDAQ:FLXN)
2017: Flexion Therapeutics: Zilretta Approved, Now What? - Flexion Therapeutics, Inc. (NASDAQ:FLXN)
2017: The Investment Case For Flexion Therapeutics - Flexion Therapeutics, Inc. (NASDAQ:FLXN)
2018: Flexion: Waiting And Watching_seekingalpha.com
2019: Flexion Finding Traction_seekingalpha.com
2019: Flexion Therapeutics shares soar after FDA approves change to label on knee pain treatment
2019: Flexion Therapeutics: A Second (And More) Life For Zilretta_seekingalpha.com
2019: Flexion Therapeutics: Holding Its Own_seekingalpha.com
2019: Flexion Therapeutics: Stock Rebounds After FDA Delays ZILRETTA Decision_seekingalpha.com
2020: The Play On Flexion Therapeutics Now
2021: Flexion Therapeutics: Bullish On The Buyout
2021: Flexion Therapeutics: Fighting Through COVID-19 Headwinds
2021: It's Time To Buy Flexion Therapeutics As Revenue Is Expected To Grow
2021: The Right Call On Frustrating Flexion Therapeutics
Focused on anti-inflammatory and analgesic pathways for the treatment of musculoskeletal conditions, beginning with osteoarthritis (OA).
Specialty pharmaceutical company developing novel, long-acting, injectable pain therapies.
Zilretta received FDA approval to treat the pain associated with osteoarthritis {OA} of the knee in October of 2017